The CEOs of CVS Health and UnitedHealth Group praised pharmacy benefit managers and promised transparency during investor ...

The Arkansas House and Senate have approved a bill that would force pharmacy benefit managers from holding a pharmacy license ...

Nowadays, the Dallas-based billionaire spends the majority of his time taking on a $5 trillion opponent: the U.S. healthcare ...

Guggenheim kicked off coverage of Cigna with a Buy rating and a $384 target, praising its nimble healthcare strategy and reliable financial footing. The firm lauded Cigna’s flexible approach and low ...

Analysts have recently evaluated CVS Health and provided 12-month price targets. The average target is $74.12, accompanied by ...

Arkansas lawmakers on both sides of the aisle have come together to file a bill that would stop pharmacy benefit managers—the middlemen who negotiate with insur ...

A bill to help independent pharmacies stay open in Alabama unanimously passed both the House and Senate on Tuesday, sending it to Gov. Kay Ivey’s desk. SB252, known as “The Community Pharmacy Relief ...

CVS Health Inc (NYSE:CVS) on Tuesday named Brian Newman as executive vice president and chief financial officer designate, ...

Leading pharmacy benefit managers are shifting away from lucrative rebates on biologic drugs and toward lower-cost biosimilar ...

The U.S. Federal Trade Commission’s lawsuit against major pharmacy benefit managers, including UnitedHealth Group’s Optum, ...

Although elevated after 2023 acquisitions, CVS’ financial position remains manageable, in our opinion, and investors should note that CVS intends to maintain a solid investment-grade credit rating.

CVS Health is a BUY. Undervalued with growth potential, it outshines competitors despite sector challenges. See more on CVS ...